Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

48.84 -0.40 (-0.81%)
Streaming Delayed Price Updated: 3:47 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗
The dispute centers around Tesaro’s participation in PD-1 trials. 
Via Stocktwits
Topics Lawsuit
News headline image
GSK PLC-SPON ADR (NYSE:GSK) Presents a High-Probability Technical Breakout Setup ↗
GSK stock shows strong technical momentum and a high-quality consolidation pattern, indicating a potential breakout opportunity for traders. 
Via Chartmill
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries. 
Via Stocktwits
Topics ETFs
News headline image
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season. 
Via Stocktwits
Topics Economy Government
News headline image
The Best Healthcare Stock to Hold in Uncertain Times ↗
Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
GSK Buys Global Rights To Preclinical Cancer Therapy For $357M ↗
Via Stocktwits
News headline image
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga
News headline image
Looking Into GSK PLC's Recent Short Interest ↗
 
Via Benzinga
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
News headline image
The Fading Luster: Is the "Gold Rush Over" While Stocks Remain "Overheated"?
The financial markets are currently grappling with a potent and increasingly vocal narrative: the "gold rush is over" for commodities, particularly gold, while the stock market, especially in certain... 
Via MarketMinute
Topics Artificial Intelligence Cannabis ETFs
News headline image
AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency
The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing... 
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
News headline image
2 High-Yield Stocks With Fresh Catalysts ↗
Income investors can capture yields above 5% from companies executing business transformations. 
Via The Motley Fool
Topics Lawsuit
News headline image
Navigating the Turbulence: Understanding Market Volatility Amidst Record Highs
As late 2025 unfolds, the global stock market presents a fascinating paradox: major U.S. indices, including the S&P 500, Dow Jones Industrial Average (NYSE: ^DJI), and Nasdaq Composite (NASDAQ: ^IXIC),... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Bonds
News headline image
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 ↗
GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2025 outlook. 
Via Benzinga
News headline image
GSK Jumps After Hiked 2025 Guidance Widely Outperforms Expectations ↗
GSK stock rose early Wednesday on strong 2025 guidance on the back of its third-quarter sales and earnings beat. 
Via Investor's Business Daily
News headline image
Dow Jones Soars to New Record High Amidst Wave of Optimism, Signaling Robust Market Confidence
The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep ↗
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial. 
Via Benzinga
News headline image
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short ↗
The company won approval for its drug, Blenrep. But it wasn't enough. 
Via Investor's Business Daily
News headline image
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce ↗
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff. 
Via Benzinga
News headline image
Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment ↗
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
News headline image
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
News headline image
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
News headline image
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.